BriaCell Therapeutics Corp. Warrant (BCTXW)
Company News
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics plans to consolidate its common shares at a 10:1 ratio to maintain Nasdaq listing requirements, effective August 25, 2025.
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.